<p>NewAmsterdam Pharma Co（納斯達克股票代碼：NAMS）在過去三個月內被 5 位分析師分析，顯示出從看漲到看跌的多樣化觀點。</p>
<p>下表提供了他們最近評級的簡要概覽，展示了過去 30 天情緒的變化，並與前幾個月進行比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師通過對 12 個月價格目標的評估提供了更深入的見解，顯示出平均目標為 44.8 美元，最高估計為 50.00 美元，最低估計為 37.00 美元。這一上升趨勢顯而易見，目前的平均值較之前的平均價格目標 39.40 美元增加了 13.71%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769018478_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769018478_0.png"/></p>
<h2>分析分析師評級：詳細拆解</h2>
<p>通過審查最近的分析師行動，我們獲得了金融專家對 NewAmsterdam Pharma Co 的看法。以下摘要概述了主要分析師、他們最近的評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超越大盤</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>James Condulis</td>
<td>Stifel</td>
<td>上調</td>
<td>買入</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>上調</td>
<td>中性</td>
<td>$37.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超越大盤</td>
<td>$44.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>上調</td>
<td>買入</td>
<td>$46.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師根據不斷變化的市場條件和公司表現頻繁更新他們的建議。無論是 ‘維持’，‘上調’ 還是 ‘下調’ 他們的立場，反映了他們對 NewAmsterdam Pharma Co 最近發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析師揭示了股票的定性評估，從 ‘超越大盤’ 到 ‘表現不佳’。這些評級提供了對 NewAmsterdam Pharma Co 相對於更廣泛市場表現預期的見解。</li>
<li><strong>價格目標：</strong> 分析師評估價格目標的動態，為 NewAmsterdam Pharma Co 股票的未來價值提供估計。這一比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
<p>理解這些分析師評估與關鍵財務指標相結合，可以為 NewAmsterdam Pharma Co 的市場地位提供有價值的見解。保持信息靈通，做出經過深思熟慮的決策，參考我們的評級表。</p>
<p>隨時瞭解 NewAmsterdam Pharma Co 的分析師評級。</p>
<h2>更好地瞭解 NewAmsterdam Pharma Co</h2>
<p>NewAmsterdam Pharma Co NV 是一家晚期生物製藥公司，致力於改善代謝疾病患者的護理，目前批准的療法尚未足夠或耐受性差。其產品 obicetrapib 是一種新一代口服低劑量 CETP 抑制劑，旨在克服當前 LDL-C 降低治療的侷限性。</p>
<h3>分析 NewAmsterdam Pharma Co 的財務表現</h3>
<p><strong>市值分析：</strong> 反映出規模較小，該公司的市值低於行業平均水平。這可能歸因於增長預期或運營能力等因素。</p>
<p><strong>收入增長：</strong> NewAmsterdam Pharma Co 在過去 3 個月的收入增長面臨挑戰。截至 2025 年 9 月 30 日，該公司經歷了約 <strong>-98.8%</strong> 的收入下降。這表明公司的頂線收益減少。與競爭對手相比，該公司的增長率低於醫療保健行業的平均水平。</p>
<p><strong>淨利潤率：</strong> NewAmsterdam Pharma Co 的淨利潤率低於行業標準，表明在實現強勁盈利能力方面面臨困難。淨利潤率為 <strong>-20691.09%</strong>，該公司可能在有效控制成本方面遇到挑戰。</p>
<p><strong>股本回報率（ROE）：</strong> NewAmsterdam Pharma Co 的 ROE 低於行業平均水平，表明在最大化股本回報方面面臨挑戰。ROE 為 <strong>-9.56%</strong>，該公司可能在實現最佳財務表現方面面臨障礙。</p>
<p><strong>資產回報率（ROA）：</strong> NewAmsterdam Pharma Co 的 ROA 低於行業平均水平，表明在有效利用資產方面可能面臨挑戰。ROA 為 <strong>-8.99%</strong>，該公司可能在實現最佳財務回報方面面臨障礙。</p>
<p><strong>債務管理：</strong> NewAmsterdam Pharma Co 的債務與股本比率低於行業平均水平，為 <strong>0.0</strong>，反映出對債務融資的依賴較低，採取了更為保守的財務策略。</p>
<h2>什麼是分析師評級？</h2>
<p>評級來自分析師，或在銀行和金融系統內的專家，他們為特定股票或定義的行業報告（通常每季度一次）。分析師通常從公司電話會議和會議、財務報表以及與重要內部人士的對話中獲取信息，以做出決策。</p>
<p>一些分析師還會提供增長預期、收益和收入等指標的預測，以進一步指導股票。使用分析師評級的投資者應注意，這些專業建議來自人類，可能會出現錯誤。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>

NAMS

<p>NewAmsterdam Pharma Co（納斯達克代碼：NAMS）在過去三個月內獲得了 5 位分析師的混合評級，平均 12 個月目標價為 44.8 美元，較之前的目標價反映出 13.71% 的增長。分析師們提高了他們的評級，其中 RBC Capital 和 Stifel 的升級尤為顯著。然而，該公司面臨挑戰，包括收入大幅下降 98.8% 和淨利潤率為-20691.09%。儘管存在這些問題，其債務與股本比率仍然較低，表明其採取了保守的財務策略。該公司專注於開發代謝疾病的治療方案</p>

<p>NewAmsterdam Pharma Co (NASDAQ: NAMS) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma Co（納斯達克股票代碼：NAMS）在過去三個月內被 5 位分析師分析，顯示出從看漲到看跌的多樣化觀點。</p>
</div><p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他們最近評級的簡要概覽，展示了過去 30 天情緒的變化，並與前幾個月進行比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $44.8, a high estimate of $50.00, and a low estimate of $37.00. This upward trend is apparent, with the current average reflecting a 13.71% increase from the previous average price target of $39.40.</p>
<div class="lb-trans"><p>分析師通過對 12 個月價格目標的評估提供了更深入的見解，顯示出平均目標為 44.8 美元，最高估計為 50.00 美元，最低估計為 37.00 美元。這一上升趨勢顯而易見，目前的平均值較之前的平均價格目標 39.40 美元增加了 13.71%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769018478_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769018478_0.png"/></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<div class="lb-trans"><h2>分析分析師評級：詳細拆解</h2>
</div><p>In examining recent analyst actions, we gain insights into how financial experts perceive NewAmsterdam Pharma Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過審查最近的分析師行動，我們獲得了金融專家對 NewAmsterdam Pharma Co 的看法。以下摘要概述了主要分析師、他們最近的評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>James Condulis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超越大盤</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>James Condulis</td>
<td>Stifel</td>
<td>上調</td>
<td>買入</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>上調</td>
<td>中性</td>
<td>$37.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超越大盤</td>
<td>$44.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>上調</td>
<td>買入</td>
<td>$46.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NewAmsterdam Pharma Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of NewAmsterdam Pharma Co compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of NewAmsterdam Pharma Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師根據不斷變化的市場條件和公司表現頻繁更新他們的建議。無論是 ‘維持’，‘上調’ 還是 ‘下調’ 他們的立場，反映了他們對 NewAmsterdam Pharma Co 最近發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析師揭示了股票的定性評估，從 ‘超越大盤’ 到 ‘表現不佳’。這些評級提供了對 NewAmsterdam Pharma Co 相對於更廣泛市場表現預期的見解。</li>
<li><strong>價格目標：</strong> 分析師評估價格目標的動態，為 NewAmsterdam Pharma Co 股票的未來價值提供估計。這一比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
</div><p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into NewAmsterdam Pharma Co's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<div class="lb-trans"><p>理解這些分析師評估與關鍵財務指標相結合，可以為 NewAmsterdam Pharma Co 的市場地位提供有價值的見解。保持信息靈通，做出經過深思熟慮的決策，參考我們的評級表。</p>
</div><p>Stay up to date on NewAmsterdam Pharma Co analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 NewAmsterdam Pharma Co 的分析師評級。</p>
</div><h2>Get to Know NewAmsterdam Pharma Co Better</h2>
<div class="lb-trans"><h2>更好地瞭解 NewAmsterdam Pharma Co</h2>
</div><p>NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma Co NV 是一家晚期生物製藥公司，致力於改善代謝疾病患者的護理，目前批准的療法尚未足夠或耐受性差。其產品 obicetrapib 是一種新一代口服低劑量 CETP 抑制劑，旨在克服當前 LDL-C 降低治療的侷限性。</p>
</div><h3>Breaking Down NewAmsterdam Pharma Co's Financial Performance</h3>
<div class="lb-trans"><h3>分析 NewAmsterdam Pharma Co 的財務表現</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 反映出規模較小，該公司的市值低於行業平均水平。這可能歸因於增長預期或運營能力等因素。</p>
</div><p><strong>Revenue Growth:</strong> NewAmsterdam Pharma Co's revenue growth over a period of 3M has faced challenges. As of 30 September, 2025, the company experienced a revenue decline of approximately <strong>-98.8%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> NewAmsterdam Pharma Co 在過去 3 個月的收入增長面臨挑戰。截至 2025 年 9 月 30 日，該公司經歷了約 <strong>-98.8%</strong> 的收入下降。這表明公司的頂線收益減少。與競爭對手相比，該公司的增長率低於醫療保健行業的平均水平。</p>
</div><p><strong>Net Margin:</strong> NewAmsterdam Pharma Co's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-20691.09%,</strong> the company may encounter challenges in effective cost control.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> NewAmsterdam Pharma Co 的淨利潤率低於行業標準，表明在實現強勁盈利能力方面面臨困難。淨利潤率為 <strong>-20691.09%</strong>，該公司可能在有效控制成本方面遇到挑戰。</p>
</div><p><strong>Return on Equity (ROE):</strong> NewAmsterdam Pharma Co's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-9.56%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> NewAmsterdam Pharma Co 的 ROE 低於行業平均水平，表明在最大化股本回報方面面臨挑戰。ROE 為 <strong>-9.56%</strong>，該公司可能在實現最佳財務表現方面面臨障礙。</p>
</div><p><strong>Return on Assets (ROA):</strong> NewAmsterdam Pharma Co's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-8.99%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> NewAmsterdam Pharma Co 的 ROA 低於行業平均水平，表明在有效利用資產方面可能面臨挑戰。ROA 為 <strong>-8.99%</strong>，該公司可能在實現最佳財務回報方面面臨障礙。</p>
</div><p><strong>Debt Management:</strong> NewAmsterdam Pharma Co's debt-to-equity ratio is below the industry average at <strong>0.0</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> NewAmsterdam Pharma Co 的債務與股本比率低於行業平均水平，為 <strong>0.0</strong>，反映出對債務融資的依賴較低，採取了更為保守的財務策略。</p>
</div><h2>What Are Analyst Ratings?</h2>
<div class="lb-trans"><h2>什麼是分析師評級？</h2>
</div><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<div class="lb-trans"><p>評級來自分析師，或在銀行和金融系統內的專家，他們為特定股票或定義的行業報告（通常每季度一次）。分析師通常從公司電話會議和會議、財務報表以及與重要內部人士的對話中獲取信息，以做出決策。</p>
</div><p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<div class="lb-trans"><p>一些分析師還會提供增長預期、收益和收入等指標的預測，以進一步指導股票。使用分析師評級的投資者應注意，這些專業建議來自人類，可能會出現錯誤。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>
</div>

評估 NewAmsterdam Pharma 公司：5 位金融分析師的深入見解